Nuvectis Pharma Q3 net loss widens on licensing and R&D costs

By Reuters News


Overview

  • US biopharma firm's Q3 net loss widened, driven by upfront licensing payments and higher R&D spend

  • Company ended Q3 with $140.7 mln in cash, extending runway into 2H 2029

  • Company completed in-licensing of two late-stage drug candidates, advancing clinical pipeline


Outlook

  • Company expects to provide an update on FDA discussions for ciprocopan in PNH before year-end

  • Nuvectis plans to submit U.S. INDs for NXP100 and NXP200 by year-end

  • Company expects cash position to fund operations into 2H 2029


Result Drivers

  • UPFRONT LICENSING COSTS - Q3 net loss included a $20 mln upfront payment for the NXP100 and NXP200 license agreement

  • HIGHER R&D EXPENSES - Research and development expenses rose, mainly due to the license payment, milestone costs, increased compensation and clinical trial expenses

  • INCREASED G&A COSTS - General and administrative expenses increased, mainly from higher professional and consulting services and employee compensation


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$1.02

Q3 Net Loss

$30.07 mln

Q3 Operating Loss

$31.05 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Nuvectis Pharma Inc is $35.00, about 81% above its November 3 closing price of $19.34


Reuters Recommended Reads

  • Nov 3 - Compass Pathways Q3 net loss narrows on lower R&D charges

  • Nov 3 - Spyre Therapeutics Q3 net loss widens more than expected on higher trial costs

  • Nov 3 - Beam Therapeutics posts wider than expected Q3 net loss as revenue drops


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk